# Vyome Holdings, Inc: financial statements, quarterly

HIND · Nasdaq · CIK 1427570 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hind.md) · [Financials](/companies/hind/financials.md) · [Filings](/companies/hind/filings.md) · [Insiders](/companies/hind/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hind/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [2,155](/filings/0001558370-24-015732.md) | [1,982 d](/filings/0001558370-25-004477.md) | [1,944](/filings/0001558370-25-008031.md) | [1,965](/filings/0001558370-25-011594.md) | [2,292](/filings/0001558370-24-015732.md) | [1,805 d](/filings/0001558370-25-004477.md) | [1,113](/filings/0001558370-25-008031.md) | [1,242](/filings/0001558370-25-011594.md) | [34.6](/filings/0001213900-25-110980.md) | [36.6 d](/filings/0001213900-26-029500.md) | [31.6](/filings/0001213900-26-055058.md) | [27.0](/filings/0001213900-26-088402.md) |
| Cost of revenue | $k | [867](/filings/0001558370-24-015732.md) | [140 d](/filings/0001558370-25-004477.md) | [779](/filings/0001558370-25-008031.md) | [831](/filings/0001558370-25-011594.md) | [47.4](/filings/0001213900-25-110980.md) | [(1.3) d](/filings/0001213900-26-029500.md) | [44.2](/filings/0001213900-26-055058.md) | [25.7](/filings/0001213900-26-088402.md) | [16.6](/filings/0001213900-25-110980.md) | [14.5 d](/filings/0001213900-26-029500.md) | [14.9](/filings/0001213900-26-055058.md) | [15.3](/filings/0001213900-26-088402.md) |
| Gross profit | $k | [1,288](/filings/0001558370-24-015732.md) | [1,842 d](/filings/0001558370-25-004477.md) | [1,165](/filings/0001558370-25-008031.md) | [1,134](/filings/0001558370-25-011594.md) | [37.1](/filings/0001213900-25-110980.md) | [62.8 d](/filings/0001213900-26-029500.md) | [154](/filings/0001213900-26-055058.md) | [24.2](/filings/0001213900-26-088402.md) | [18.1](/filings/0001213900-25-110980.md) | [22.1 d](/filings/0001213900-26-029500.md) | [16.6](/filings/0001213900-26-055058.md) | [11.7](/filings/0001213900-26-088402.md) |
| Research and development | $k | [542](/filings/0001558370-24-015732.md) | [739 d](/filings/0001558370-25-004477.md) | [484](/filings/0001558370-25-008031.md) | [399](/filings/0001558370-25-011594.md) | [66.8](/filings/0001213900-25-110980.md) | [67.5 d](/filings/0001213900-26-029500.md) | [90.3](/filings/0001213900-26-055058.md) | [80.1](/filings/0001213900-26-088402.md) | [39.7](/filings/0001213900-25-110980.md) | [378 d](/filings/0001213900-26-029500.md) | [666](/filings/0001213900-26-055058.md) | [507](/filings/0001213900-26-088402.md) |
| Selling, general and administrative | $k | [1,791](/filings/0001558370-24-015732.md) | [1,398 d](/filings/0001558370-24-004559.md) | [1,019](/filings/0001558370-24-008304.md) | [670](/filings/0001558370-24-012246.md) | [247](/filings/0001213900-25-110980.md) | [247 d](/filings/0001213900-26-029500.md) | [260](/filings/0001213900-26-055058.md) | [265](/filings/0001213900-26-088402.md) | [844](/filings/0001213900-25-110980.md) | [996 d](/filings/0001213900-26-029500.md) | [478](/filings/0001213900-26-055058.md) | [365](/filings/0001213900-26-088402.md) |
| Operating income | $k | [(3,880)](/filings/0001558370-24-015732.md) | [(1,895) d](/filings/0001558370-25-004477.md) | [(2,210)](/filings/0001558370-25-008031.md) | [(2,054)](/filings/0001558370-25-011594.md) | [(281)](/filings/0001213900-25-110980.md) | [(256) d](/filings/0001213900-26-029500.md) | [(199)](/filings/0001213900-26-055058.md) | [(324)](/filings/0001213900-26-088402.md) | [(8,574)](/filings/0001213900-25-110980.md) | [(1,355) d](/filings/0001213900-26-029500.md) | [(1,130)](/filings/0001213900-26-055058.md) | [(863)](/filings/0001213900-26-088402.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | [45.7](/filings/0001213900-25-110980.md) | [52.8 d](/filings/0001213900-26-029500.md) | [55.0](/filings/0001213900-26-055058.md) | [56.1](/filings/0001213900-26-088402.md) | [25.6](/filings/0001213900-25-110980.md) | [9.9 d](/filings/0001213900-26-029500.md) | [2.8](/filings/0001213900-26-055058.md) | [3.3](/filings/0001213900-26-088402.md) |
| Income tax | $k | [3.0](/filings/0001558370-24-015732.md) | [31.0 d](/filings/0001558370-25-004477.md) | [14.0](/filings/0001558370-25-008031.md) | [15.0](/filings/0001558370-25-011594.md) | [6.0](/filings/0001558370-24-015732.md) | [5.0 d](/filings/0001558370-25-004477.md) | [7.0](/filings/0001558370-25-008031.md) | [8.0](/filings/0001558370-25-011594.md) | not reported | not reported | not reported | not reported |
| Net income | $k | [(3,534)](/filings/0001558370-24-015732.md) | [(1,698) d](/filings/0001558370-25-004477.md) | [(2,193)](/filings/0001558370-25-008031.md) | [(1,595)](/filings/0001558370-25-011594.md) | [(548)](/filings/0001213900-25-110980.md) | [(307) d](/filings/0001213900-26-029500.md) | [(294)](/filings/0001213900-26-055058.md) | [(309)](/filings/0001213900-26-088402.md) | [(8,434)](/filings/0001213900-25-110980.md) | [(1,225) d](/filings/0001213900-26-029500.md) | [(963)](/filings/0001213900-26-055058.md) | [(686)](/filings/0001213900-26-088402.md) |
| Diluted EPS | $ per share | [(59.36)](/filings/0001558370-24-015732.md) | not reported | [(135.37)](/filings/0001558370-25-008031.md) | [(91.56)](/filings/0001558370-25-011594.md) | [(1419.10)](/filings/0001213900-25-110980.md) | not reported | [(761.59)](/filings/0001213900-26-055058.md) | [(799.90)](/filings/0001213900-26-088402.md) | [(3.12)](/filings/0001213900-25-110980.md) | not reported | [(0.15)](/filings/0001213900-26-055058.md) | [(0.10)](/filings/0001213900-26-088402.md) |
| Basic EPS | $ per share | [(59.36)](/filings/0001558370-24-015732.md) | not reported | [(135.37)](/filings/0001558370-25-008031.md) | [(91.56)](/filings/0001558370-25-011594.md) | [(1419.10)](/filings/0001213900-25-110980.md) | not reported | [(761.59)](/filings/0001213900-26-055058.md) | [(799.90)](/filings/0001213900-26-088402.md) | [(3.12)](/filings/0001213900-25-110980.md) | not reported | [(0.15)](/filings/0001213900-26-055058.md) | [(0.10)](/filings/0001213900-26-088402.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1.4](/filings/0001558370-23-018344.md) | [4.5](/filings/0001558370-25-004477.md) | [2.4](/filings/0001558370-24-008304.md) | [0.0](/filings/0001213900-25-110980.md) | [0.7](/filings/0001558370-24-015732.md) | [0.1](/filings/0001213900-26-029500.md) | [2.5](/filings/0001558370-25-008031.md) | [4.1](/filings/0001558370-25-011594.md) | [5.7](/filings/0001213900-25-110980.md) | [5.0](/filings/0001213900-26-088402.md) | [8.8](/filings/0001213900-26-055058.md) | [7.9](/filings/0001213900-26-088402.md) |
| Current assets | $m | [7.4](/filings/0001558370-23-018344.md) | [10.3](/filings/0001558370-25-004477.md) | [7.9](/filings/0001558370-24-008304.md) | [6.1](/filings/0001558370-24-012246.md) | [5.3](/filings/0001558370-24-015732.md) | [0.3](/filings/0001213900-26-029500.md) | [6.3](/filings/0001558370-25-008031.md) | [8.9](/filings/0001558370-25-011594.md) | [6.0](/filings/0001213900-25-110980.md) | [5.4](/filings/0001213900-26-088402.md) | [9.2](/filings/0001213900-26-055058.md) | [8.2](/filings/0001213900-26-088402.md) |
| Total assets | $m | [7.8](/filings/0001558370-23-018344.md) | [10.7](/filings/0001558370-25-004477.md) | [8.2](/filings/0001558370-24-008304.md) | [6.4](/filings/0001558370-24-012246.md) | [1.3](/filings/0001213900-25-110980.md) | [1.4](/filings/0001213900-26-029500.md) | [1.4](/filings/0001213900-26-055058.md) | [9.0](/filings/0001558370-25-011594.md) | [7.0](/filings/0001213900-25-110980.md) | [6.5](/filings/0001213900-26-088402.md) | [10.2](/filings/0001213900-26-055058.md) | [9.2](/filings/0001213900-26-088402.md) |
| Current liabilities | $m | [4.5](/filings/0001558370-23-018344.md) | [3.8](/filings/0001558370-25-004477.md) | [3.5](/filings/0001558370-24-008304.md) | [3.2](/filings/0001558370-24-012246.md) | [4.0](/filings/0001558370-24-015732.md) | [5.7](/filings/0001213900-26-029500.md) | [4.1](/filings/0001558370-25-008031.md) | [3.2](/filings/0001558370-25-011594.md) | [3.1](/filings/0001213900-25-110980.md) | [2.7](/filings/0001213900-26-088402.md) | [2.1](/filings/0001213900-26-055058.md) | [1.9](/filings/0001213900-26-088402.md) |
| Total liabilities | $m | [4.7](/filings/0001558370-23-018344.md) | [4.0](/filings/0001558370-25-004477.md) | [3.7](/filings/0001558370-24-008304.md) | [3.4](/filings/0001558370-24-012246.md) | [4.1](/filings/0001558370-24-015732.md) | [5.8](/filings/0001213900-26-029500.md) | [5.3](/filings/0001558370-25-008031.md) | [3.2](/filings/0001558370-25-011594.md) | [3.1](/filings/0001213900-25-110980.md) | [2.7](/filings/0001213900-26-088402.md) | [2.1](/filings/0001213900-26-055058.md) | [1.9](/filings/0001213900-26-088402.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | [0.8](/filings/0001558370-25-011594.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [3.1](/filings/0001558370-24-015732.md) | [6.7](/filings/0001558370-25-011594.md) | [4.5](/filings/0001558370-25-011594.md) | [3.0](/filings/0001558370-25-011594.md) | [1.5](/filings/0001558370-24-015732.md) | [(4.4)](/filings/0001213900-25-110980.md) | [1.2](/filings/0001558370-25-011594.md) | [5.8](/filings/0001558370-25-011594.md) | [2.5](/filings/0001213900-25-110980.md) | [3.8](/filings/0001213900-26-088402.md) | [8.0](/filings/0001213900-26-088402.md) | [7.3](/filings/0001213900-26-088402.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,780) d](/filings/0001558370-24-015732.md) | [(2,457) d](/filings/0001558370-25-004477.md) | [(2,072)](/filings/0001558370-25-008031.md) | [(1,357) d](/filings/0001558370-25-011594.md) | [2,818 d](/filings/0001213900-25-110980.md) | [(3.0) d](/filings/0001213900-26-029500.md) | [(204)](/filings/0001213900-26-055058.md) | [(306) d](/filings/0001213900-26-088402.md) | [(1,761) d](/filings/0001213900-25-110980.md) | [(1,478) d](/filings/0001213900-26-029500.md) | [(1,436)](/filings/0001213900-26-055058.md) | [(904) d](/filings/0001213900-26-088402.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001558370-24-015732.md) | [0.0 d](/filings/0001558370-25-004477.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [386](/filings/0001558370-23-013645.md) | [451](/filings/0001558370-23-018344.md) | [1,708](/filings/0001558370-24-008304.md) | [3,249](/filings/0001558370-24-012246.md) | [59.5](/filings/0001558370-24-015732.md) | [16.2](/filings/0001558370-25-008031.md) | [17.4](/filings/0001558370-25-011594.md) | [0.4](/filings/0001213900-25-110980.md) | [0.4](/filings/0001213900-26-055058.md) | [1,169](/filings/0001558370-25-011594.md) | [2,758](/filings/0001213900-25-110980.md) | [6,690](/filings/0001213900-26-055058.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 7,018,528 at 2026-08-12, from the cover of the [10-Q filed 2026-08-12](/filings/0001213900-26-088402.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.